Alembic Pharmaceuticals has received the Food and Drug Administration’s blessing for desvenlafaxine extended-release tablets in a 25-mg dosage strength.
The product, which is the generic of Wyeth Pharma’s Pristiq extended-release tablets 25 mg, is indicated for the treatment of major depressive disorder, or MDD.
Desvenlafaxine extended-release tablets 25 mg had a market value of approximately $13.3 million for the 12 months ending December 2017, according to IQVIA.